It seems reimbursement headwinds ultimately proved too much for prescription digital medicine company Akili, Inc., which announced on 13 September that it would convert to a non-prescription direct-to-consumer model to get its game-based ADHD treatment into the hands of more patients.
“We've been running a prescription model that has dependencies on healthcare stakeholders who we don't solve a direct problem for. Friction here was honestly more than we anticipated